We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

6 hedge funds and large institutions have $1.79M invested in Pacer BioThreat Strategy ETF in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 4 → 6 (+2)

11% more capital invested

Capital invested by funds: $1.6M → $1.79M (+$183K)

0.14% less ownership

Funds ownership: 49.65% → 49.51% (-0.14%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$33.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$9.17K
3
AF
Allworth Financial
California
+$4.57K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$24.9K
2
Osaic Holdings
Osaic Holdings
Arizona
-$15.8K
3
IAIM
International Assets Investment Management
Florida
-$11.1K

VIRS Hedge Fund Activity: Q1 2024 in Review

6 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q1 2024, worth a combined $1.79M — up 11% from $1.6M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VIRS positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $33.3K. The largest seller was UBS Group, cutting an estimated $24.9K.

  • 6 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q1 2024, up from 4 in Q4 2023.
  • Funds reported $1.79M of Pacer BioThreat Strategy ETF stock for Q1 2024, up 11% quarter-over-quarter.
  • 2 funds opened new Pacer BioThreat Strategy ETF positions in Q1 2024 and 0 closed out, a net change of +2 holders.
  • The largest Pacer BioThreat Strategy ETF buyer in Q1 2024 was Royal Bank of Canada, an estimated $33.3K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q1 2024 was UBS Group, an estimated $24.9K sold.

Based on aggregated 13F filings for Q1 2024.